Detoxication enzymes and chemoprevention - PubMed (original) (raw)
Review
Detoxication enzymes and chemoprevention
J Wilkinson 4th et al. Proc Soc Exp Biol Med. 1997 Nov.
Abstract
Detoxication enzymes protect cells from a wide variety of xenobiotics and endogenous toxins. Current data suggest that the balance between the Phase I carcinogen-activating enzymes and the Phase II detoxifying enzymes is critical to determining an individual's risk for cancer. Human deficiencies in Phase II enzyme activity, specifically glutathione-S-transferase (GST), have been identified and associated with increased risk for colon cancer. The increased frequency of the GST M1 null genotype among individuals with primarily smoking-related cancers has been documented. Induction of Phase II enzymes by naturally occurring or synthetic agents represents a promising strategy for cancer prevention. Both the required characteristics of potential chemopreventive agents and the role of the antioxidant response element in the monofunctional induction of Phase II enzymes have been discussed. The synthetic dithiolthione oltipraz induces a battery of Phase II enzymes and inhibits chemically induced tumors in a variety of target organs. Its ability to induce Phase II enzymes in human colon tissue and blood lymphocytes has been reported. Other promising inducers with chemopreventive activity include the isothiocyanates and polyphenols. These data collectively support the future development of Phase II enzyme inducers as clinical chemopreventive agents.
Similar articles
- Glutathione S-transferases--biomarkers of cancer risk and chemopreventive response.
Clapper ML, Szarka CE. Clapper ML, et al. Chem Biol Interact. 1998 Apr 24;111-112:377-88. doi: 10.1016/s0009-2797(97)00174-9. Chem Biol Interact. 1998. PMID: 9679568 Review. - Chemoprotection by organosulfur inducers of phase 2 enzymes: dithiolethiones and dithiins.
Kensler TW, Curphey TJ, Maxiutenko Y, Roebuck BD. Kensler TW, et al. Drug Metabol Drug Interact. 2000;17(1-4):3-22. doi: 10.1515/dmdi.2000.17.1-4.3. Drug Metabol Drug Interact. 2000. PMID: 11201301 Review. - Effects of cruciferous vegetables and their constituents on drug metabolizing enzymes involved in the bioactivation of DNA-reactive dietary carcinogens.
Steinkellner H, Rabot S, Freywald C, Nobis E, Scharf G, Chabicovsky M, Knasmüller S, Kassie F. Steinkellner H, et al. Mutat Res. 2001 Sep 1;480-481:285-97. doi: 10.1016/s0027-5107(01)00188-9. Mutat Res. 2001. PMID: 11506821 Review. - Role of phase 2 enzyme induction in chemoprotection by dithiolethiones.
Kwak MK, Egner PA, Dolan PM, Ramos-Gomez M, Groopman JD, Itoh K, Yamamoto M, Kensler TW. Kwak MK, et al. Mutat Res. 2001 Sep 1;480-481:305-15. doi: 10.1016/s0027-5107(01)00190-7. Mutat Res. 2001. PMID: 11506823 Review. - Oltipraz is a bifunctional inducer activating both phase I and phase II drug-metabolizing enzymes via the xenobiotic responsive element.
Miao W, Hu L, Kandouz M, Batist G. Miao W, et al. Mol Pharmacol. 2003 Aug;64(2):346-54. doi: 10.1124/mol.64.2.346. Mol Pharmacol. 2003. PMID: 12869639
Cited by
- Aberrant crypt foci and AgNORs as putative biomarkers to evaluate the chemopreventive efficacy of pronyl-lysine in rat colon carcinogenesis.
Panneer Selvam J, Aranganathan S, Nalini N. Panneer Selvam J, et al. Invest New Drugs. 2008 Dec;26(6):531-40. doi: 10.1007/s10637-008-9122-7. Epub 2008 Feb 29. Invest New Drugs. 2008. PMID: 18309460 - Ulva lactuca polysaccharides prevent Wistar rat breast carcinogenesis through the augmentation of apoptosis, enhancement of antioxidant defense system, and suppression of inflammation.
Abd-Ellatef GF, Ahmed OM, Abdel-Reheim ES, Abdel-Hamid AZ. Abd-Ellatef GF, et al. Breast Cancer (Dove Med Press). 2017 Feb 27;9:67-83. doi: 10.2147/BCTT.S125165. eCollection 2017. Breast Cancer (Dove Med Press). 2017. PMID: 28280387 Free PMC article. - Oxidative stress, free radicals and antioxidants: potential crosstalk in the pathophysiology of human diseases.
Chaudhary P, Janmeda P, Docea AO, Yeskaliyeva B, Abdull Razis AF, Modu B, Calina D, Sharifi-Rad J. Chaudhary P, et al. Front Chem. 2023 May 10;11:1158198. doi: 10.3389/fchem.2023.1158198. eCollection 2023. Front Chem. 2023. PMID: 37234200 Free PMC article. Review. - Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis.
Hull J, Thomson AH. Hull J, et al. Thorax. 1998 Dec;53(12):1018-21. doi: 10.1136/thx.53.12.1018. Thorax. 1998. PMID: 10195071 Free PMC article. - Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent.
Taioli E, Flores-Obando RE, Agalliu I, Blanchet P, Bunker CH, Ferrell RE, Jackson M, Kidd LC, Kolb S, Lavender NA, McFarlane-Anderson N, Morrison SS, Multigner L, Ostrande EA, Park JY, Patrick AL, Rebbeck TR, Romana M, Stanford JL, Ukoli F, Vancleave TT, Zeigler-Johnson CM, Mutetwa B, Ragin C. Taioli E, et al. Carcinogenesis. 2011 Sep;32(9):1361-5. doi: 10.1093/carcin/bgr119. Epub 2011 Jun 24. Carcinogenesis. 2011. PMID: 21705483 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials